David Evans, CEO of Nexus6 said "this partnership between Nexus6 and MicroDose will enable the drug delivery marketplace to access leading edge data collection and transmission capabilities, thereby increasing pharmaceutical adherence, improving patient well-being and reducing overall health care costs."
About the MicroDose DPI
The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. Microdose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.
About MicroDose Technologies
MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery and specialty pharmaceuticals company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies and products for the pharmaceutical and biotechnology industries.
MicroDose's partnered programs include; multi-product development and licensing agreements with Merck and Co. and Novartis, the development of an inhaled insulin product through MicroDose's QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the
|SOURCE MicroDose Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved